NanoViricides, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2023, compared with the year ended June 30, 2022. Although the request metadata says “2022 Q4,” this filing is an annual report for fiscal 2023, not a quarterly filing. NanoViricides is a clinical-stage antiviral drug developer with no commercial products or revenue.
Financial performance and liquidity
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $6.39 million | $5.78 million |
| General and administrative expense | $2.55 million | $2.33 million |
| Net loss | $8.59 million | $8.11 million |
| Basic and diluted loss per share | $0.74 | $0.70 |
| Net cash used in operating activities | $5.67 million | $5.89 million |
| Cash and cash equivalents at year-end | $8.15 million | $14.07 million |
- Operating expenses rose approximately $830,000, primarily reflecting higher R&D and G&A costs. Management attributed the net-loss increase mainly to license milestone expenses. Interest income rose to approximately $356,000 from $12,000.
- At June 30, 2023, total assets were $16.90 million, total liabilities $2.03 million, and stockholders’ equity $14.87 million. Current liabilities were $534,000; the additional $1.50 million related-party liability was non-current.
- Cash declined by $5.92 million during the year. The company reported an accumulated deficit of $131.08 million and expects continuing losses; its deferred tax asset of approximately $37.39 million was fully offset by a valuation allowance.
- Management said available cash was expected to fund planned operations through October 2024 and at least 12 months from filing, but additional capital will be needed for later-stage trials and continued development. These are estimates, not assurances.
- The company had a $150 million shelf registration available. In August 2023, it also filed a prospectus supplement for potential ATM common-stock sales of up to approximately $5.71 million. Either could result in dilution.
Business developments and changes
- Lead candidate NV-387, formulated as NV-CoV-2 oral syrup and gummies, entered Phase 1a/1b trials in India in June 2023. The trial is sponsored and managed by licensee Karveer Meditech; the company said interim healthy-volunteer cohorts had reported no adverse or serious adverse events as of the filing, while patient enrollment was still subject to Ethics Committee permission. Human efficacy has not been established in the filing.
- The filing reports preclinical activity for NV-387 against RSV and says the company intends to pursue an RSV IND and further trials, subject to resources. NV-HHV-1, a shingles skin cream, had completed IND-enabling studies; clinical development remained planned, not underway.
- R&D expense allocation shifted toward expansion: approximately $6.09 million was allocated to the pan-coronavirus program, $200,000 to RSV, and $100,000 to HerpeCide in FY 2023. The company said other programs remain constrained by resources.
- In March 2023, the company licensed NV-CoV-2 and NV-CoV-2-R to Karveer for India. NanoViricides is to reimburse trial and development costs plus a 30% manager fee; Karveer is to pay NanoViricides 70% of qualifying sales, net of specified third-party costs, if products are commercialized.
- The company redomiciled from Nevada to Delaware effective May 30, 2023. Common shares outstanding increased to 11.70 million from 11.59 million; Series A preferred shares outstanding rose to 547,674 from 484,582.
Outlook, risks, and unusual items
- Management’s near-term priorities include completing the NV-CoV-2 Phase 1a/1b trial, preparing an RSV IND, and potentially advancing NV-387 into efficacy trials. The filing provides no firm timeline for regulatory approval or commercialization and expressly says timing and cost estimates may be inaccurate.
- A $1.50 million milestone payable to TheraCour was recorded as a non-current liability at year-end after initiation of the clinical trial. In July 2023, it was replaced with a convertible promissory note bearing 12% simple annual interest and maturing January 19, 2025; conversion into Series A preferred stock is at TheraCour’s option under the note terms.
- TheraCour is a related party controlled approximately 90% by founder, President and Executive Chairman Anil Diwan. It licenses the core technology and performs development work; FY 2023 charges were approximately $2.54 million. The company’s Karveer collaboration is also related-party connected: Diwan is a passive investor and advisor, and the company accrued $100,000 of trial costs at year-end.
- Management reported a material weakness in internal control over financial reporting: insufficient timely management review of the Form 10-K. Controls were assessed as ineffective at June 30, 2023; a remediation committee had been established, but the weakness was not fully remediated.
- Key risks include clinical or regulatory failure, continued cash burn and financing dependence, potential dilution, reliance on TheraCour and external trial providers, limited staffing, and uncertainty regarding patent protection and commercialization. No material pending legal proceedings were reported.
- The independent auditor issued an unqualified opinion on the financial statements, but did not audit or express an opinion on internal control effectiveness.
Important facts for investors to verify
- Latest Phase 1a/1b trial enrollment, safety findings, patient data, and whether results can support FDA or other regulatory filings.
- Actual cash runway, subsequent financing or ATM activity, and the cost and funding plan for RSV and later-stage trials.
- Terms, balances, interest, and any conversion or repayment of the $1.50 million TheraCour note, along with future license milestones and related-party charges.
- Progress in remediating the material weakness and whether subsequent filings receive timely, effective review.
- Current share count and potential dilution from equity offerings, preferred-stock conversion upon a change of control, warrants, and other securities.